Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 11/20 | 0.61 |
| ▸ | CPT1A | P50416 | 2/20 | 0.45 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL957891 | 0.89 | CPT1A (0.58) | PTGER4CPT1ACPT1BCNR1 | |
| SCHEMBL962510 | 0.76 | CPT1A (0.56) | PTGER4CPT1ACPT1BCNR1 | |
| SCHEMBL958064 | 0.75 | CPT1A (0.75) | PTGER4CPT1ACPT1BCNR1 | |
| SCHEMBL963615 | 0.75 | PTGER4 (0.59) | PTGER4CPT1ACPT1B | |
| SCHEMBL24273643 | 0.74 | PTGER4 (0.71) | PTGER4CPT1ACNR1 | |
| SCHEMBL959696 | 0.74 | PTGER4 (0.63) | PTGER4CNR1CYP2D6MEN1KMT2A | |
| SCHEMBL957884 | 0.73 | CPT1A (0.55) | PTGER4CPT1ACPT1B | |
| SCHEMBL16341492 | 0.71 | CYP2D6 (0.56) | PTGER4CNR1CYP2D6 | |
| SCHEMBL24273440 | 0.71 | PTGER4 (0.80) | PTGER4CPT1AUSP30MEN1KMT2A | |
| SCHEMBL751010 | 0.71 | MKNK1 (0.42) | MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071628-B2 | Indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | claimed |
| US-20110015234-A1 | INDAZOLE DERIVATIVES | ACKERMANN JEAN | 2011-01-20 | — | — | US | claimed |
| EP-2079703-A1 | INDAZOLE DERIVATIVES USEFUL AS L-CPT1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-07-22 | — | — | EP | claimed |
| WO-2008052898-A1 | INDAZOLE DERIVATIVES USEFUL AS L-CPT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-08 | — | — | WO | claimed |
| US-20080103182-A1 | INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-05-01 | — | — | US | claimed |
| US-8071628-B2 | Indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20110015234-A1 | INDAZOLE DERIVATIVES | ACKERMANN JEAN | 2011-01-20 | — | — | US | disclosed |
| US-7858645-B2 | Indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| EP-2079703-A1 | INDAZOLE DERIVATIVES USEFUL AS L-CPT1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008052898-A1 | INDAZOLE DERIVATIVES USEFUL AS L-CPT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| US-20080103182-A1 | INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103182-A1 | INDAZOLE DERIVATIVES | CPT1A, CPT1B, CES1 | PTGER4 1048/4885CPT1A 1/4885CPT1B 2/4885 |
| US-20110015234-A1 | INDAZOLE DERIVATIVES | CPT1A, CPT1B, CES1 | PTGER4 1048/4885CPT1A 1/4885CPT1B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.